Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico

Kwality Pharmaceutical Ltd is pleased to announce that it has received registration for Bleomycin 15 1U in Mexico for sale and distribution.

Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally.

The projected business potential is around 1 million USD in the first year, and supplies will commence before the end of Q2FY26

Kwality Pharmaceuticals Ltd. remains committed to expanding access to high-quality medicines across global markets.

Shares of Kwality Pharmaceuticals Ltd was last trading in BSE at Rs. 1069.05 as compared to the previous close of Rs. 1078.65. The total number of shares traded during the day was 5167 in over 236 trades.

The stock hit an intraday high of Rs. 1087.40 and intraday low of 1068.00. The net turnover during the day was Rs. 5541683.00.

Source : Equity Bulls

Keywords

KwalityPharmaceuticals INE552U01010 ProductRegistration Bleomycin 15IU Vial Mexico